Developmental Programs


Our compounds are novel, first-in-class systemic integrin activators that have been shown in preclinical models to increase and prolong cell adhesion while maintaining the ability to move and migrate. In doing so, 7HP compounds are expected to augment antigen presentation and immune priming to facilitate a productive immune response against a variety of antigens including antigens from solid tumors and infectious diseases. The lead compound, 7HP349 is an oral VLA-4/LFA-1 allosteric activator that will be in Phase I testing for PD-1 refractory solid tumors, and geriatric influenza.


Immuno-oncology Program


A key factor limiting the success of immuno-oncology therapy and adoptive cell therapy is the relatively low number of tumor specific T cells that physically enter a solid tumor.  Tumors secrete agents that suppress the immune response and can actively alter their cell surface to prevent specific T cells from binding them and killing them. 7HP compounds are designed to overcome the ability of a tumor to evade the immune response by imparting on tumor specific T cells the capability to localize to, and efficiently kill, tumor cells. 


Vaccine Program


Elderly populations are most susceptible to infectious diseases and may not have an effective immune response to prophylactic vaccines. Integrins α4β1 and αLβ2 are cell adhesion molecules that are essential for a productive immune response, critical for antigen presentation and immune priming. Older subjects may be defective in dendric cell induction of integrin ligands, which may be responsible for poor immune responses and the apparent age-associated risk to influenza, coronavirus, and other infectious agents. 7HP compounds may improve integrin adhesion and memory to improve the effectiveness of prophylactic T cell vaccines.


Cord Blood Program


Cord blood stem cell transplant is potentially curative for a variety of hematologic cancers and genetic diseases.  However, the low number of stem cells in cord blood preparations limits their use primarily to pediatric patients, and can result in an increased risk of opportunistic infections, increased hospital costs, and high graft failure rates. 7HP compounds are designed to act as “cellular glue,” promoting cord blood stem cell adhesion and engraftment into the bone marrow resulting in improved patient outcomes.

Upendra Marathi, Ph.D., M.B.A.

President and CEO


Lionel Lewis, M.D.

Chief Medical Officer


William Schary, Ph.D.

Vice President of Clinical and Regulatory Affairs

​​

Richard Dixon, Ph.D.

Co-founder, Manager


Joseph Bailes, M.D.

Advisor & Manager


Daniel Von Hoff, M.D.

Advisor & Collaborator


Peter Vanderslice, Ph.D.

Co-Founder, Advisor & Collaborator


Darren Woodside, Ph.D.

Co-Founder, Advisor & Collaborator


Jason Luke, M.D., FACP

Advisor


Robert Kramer

Advisor


Jeffrey Actor, Ph.D.

Advisor & Collaborator


Adolfo García-Sastre, Ph.D.

Advisor & Collaborator

7 Hills is managed by an experienced group of pharmaceutical executives with the requisite expertise to take the Company from molecule to market—the team has successfully developed and secured FDA approval for five New Drug Products.  

Management

7 Hills Pharma is a clinical stage pharmaceutical company, developing first-in-concept integrin activators to augment immunotherapies for the treatment of drug resistant solid tumors and infectious diseases. 


About Us